200 related articles for article (PubMed ID: 33782006)
1. Clinical Impact of the Revised 2019 CLSI Levofloxacin Breakpoints in Patients with
Huang HY; Wang CF; Lu PL; Tseng SP; Wang YL; Chen TC; Chang K; Tu HP; Lin SY
Antimicrob Agents Chemother; 2021 May; 65(6):. PubMed ID: 33782006
[TBL] [Abstract][Full Text] [Related]
2. Correlation of Vitek 2 and Agar dilution for levofloxacin susceptibility testing and clinical outcomes of Enterobacterales bacteremia with 2019 CLSI breakpoints.
Huang HY; Chang YT; Lu PL; Yang TY; Wang YL; Chen TC; Wu JH; Lin SY
Diagn Microbiol Infect Dis; 2022 Dec; 104(4):115799. PubMed ID: 36215940
[TBL] [Abstract][Full Text] [Related]
3. The impact of revised CLSI cefazolin breakpoints on the clinical outcomes of Escherichia coli bacteremia.
Wang KC; Liu MF; Lin CF; Shi ZY
J Microbiol Immunol Infect; 2016 Oct; 49(5):768-774. PubMed ID: 26493889
[TBL] [Abstract][Full Text] [Related]
4. Impact of revised susceptibility breakpoints on bacteremia of Klebsiella pneumoniae: Minimum inhibitory concentration of cefazolin and clinical outcomes.
Chuang CH; Liu MF; Lin CF; Shi ZY
J Microbiol Immunol Infect; 2016 Oct; 49(5):679-684. PubMed ID: 25442869
[TBL] [Abstract][Full Text] [Related]
5. Surveillance of Fluoroquinolone Resistance in Wisconsin: Geographic Variation and Impact of Revised CLSI Breakpoints.
Lazzerini G; Lavey SC; Fox BC; Munson E
Clin Med Res; 2022 Jun; 20(2):81-88. PubMed ID: 35086853
[No Abstract] [Full Text] [Related]
6. A Multicenter Comparison of Carbapenem-Nonsusceptible Enterobacterales and Pseudomonas aeruginosa Rates in the US (2016 to 2020): Facility-Reported Rates versus Rates Based on Updated Clinical Laboratory and Standards Institute Breakpoints.
Gupta V; Yu KC; Pogue JM; Watts JA; Clancy CJ
Microbiol Spectr; 2022 Jun; 10(3):e0115822. PubMed ID: 35638777
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Ciprofloxacin and Levofloxacin Disk Diffusion and Etest Using the 2019
Humphries RM; Hindler JA; Shaffer K; Campeau SA
J Clin Microbiol; 2019 Mar; 57(3):. PubMed ID: 30567744
[TBL] [Abstract][Full Text] [Related]
8. Evaluating outcomes associated with revised fluoroquinolone breakpoints for Enterobacterales urinary tract infections: A retrospective cohort study.
Benavides TM; Aden JK; Giancola SE
Eur J Clin Microbiol Infect Dis; 2022 May; 41(5):741-749. PubMed ID: 35224677
[TBL] [Abstract][Full Text] [Related]
9. Empirical third-generation cephalosporin therapy for adults with community-onset Enterobacteriaceae bacteraemia: Impact of revised CLSI breakpoints.
Hsieh CC; Lee CH; Li MC; Hong MY; Chi CH; Lee CC
Int J Antimicrob Agents; 2016 Apr; 47(4):297-303. PubMed ID: 27005458
[TBL] [Abstract][Full Text] [Related]
10. Fluoroquinolone susceptibility testing of Salmonella enterica: detection of acquired resistance and selection of zone diameter breakpoints for levofloxacin and ofloxacin.
Sjölund-Karlsson M; Howie RL; Crump JA; Whichard JM
J Clin Microbiol; 2014 Mar; 52(3):877-84. PubMed ID: 24391204
[TBL] [Abstract][Full Text] [Related]
11. Association between minimum inhibitory concentration values and mortality risk in patients with
Sarzynski SH; Lawandi A; Warner S; Demirkale CY; Strich JR; Dekker JP; Babiker A; Li W; Kadri SS
JAC Antimicrob Resist; 2023 Apr; 5(2):dlad049. PubMed ID: 37124072
[TBL] [Abstract][Full Text] [Related]
12. Multicenter Study of the Relationship between Carbapenem MIC Values and Clinical Outcome of Patients with Acinetobacter Bacteremia.
Yang YS; Wang YC; Kuo SC; Chen CT; Liu CP; Liu YM; Chen TL; Lee YT
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28652230
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of children with enterobacteriaceae bacteremia with reduced susceptibility to ceftriaxone: do the revised breakpoints translate to improved patient outcomes?
Tamma PD; Wu H; Gerber JS; Hsu AJ; Tekle T; Carroll KC; Cosgrove SE
Pediatr Infect Dis J; 2013 Sep; 32(9):965-9. PubMed ID: 23470679
[TBL] [Abstract][Full Text] [Related]
14. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
15. Relationships among ciprofloxacin, gatifloxacin, levofloxacin, and norfloxacin MICs for fluoroquinolone-resistant Escherichia coli clinical isolates.
Becnel Boyd L; Maynard MJ; Morgan-Linnell SK; Horton LB; Sucgang R; Hamill RJ; Jimenez JR; Versalovic J; Steffen D; Zechiedrich L
Antimicrob Agents Chemother; 2009 Jan; 53(1):229-34. PubMed ID: 18838594
[TBL] [Abstract][Full Text] [Related]
16. Vancomycin 24-Hour Area under the Curve/Minimum Bactericidal Concentration Ratio as a Novel Predictor of Mortality in Methicillin-Resistant Staphylococcus aureus Bacteremia.
Britt NS; Patel N; Horvat RT; Steed ME
Antimicrob Agents Chemother; 2016 May; 60(5):3070-5. PubMed ID: 26953202
[TBL] [Abstract][Full Text] [Related]
17. A propensity score-matched analysis of the impact of minimum inhibitory concentration on mortality in patients with Pseudomonas aeruginosa bacteremia treated with cefepime or ceftazidime.
Ratliff AR; Gentry CA; Williams RJ
Diagn Microbiol Infect Dis; 2017 Apr; 87(4):376-381. PubMed ID: 28087171
[TBL] [Abstract][Full Text] [Related]
18. Risk factors and outcome of levofloxacin-resistant Elizabethkingia meningoseptica bacteraemia in adult patients in Taiwan.
Huang YC; Huang YW; Lin YT; Wang FD; Chan YJ; Yang TC
Eur J Clin Microbiol Infect Dis; 2017 Aug; 36(8):1373-1380. PubMed ID: 28265817
[TBL] [Abstract][Full Text] [Related]
19. Nosocomial methicillin-resistant Staphylococcus aureus (MRSA) bacteremia in Taiwan: mortality analyses and the impact of vancomycin, MIC = 2 mg/L, by the broth microdilution method.
Wang JL; Wang JT; Sheng WH; Chen YC; Chang SC
BMC Infect Dis; 2010 Jun; 10():159. PubMed ID: 20529302
[TBL] [Abstract][Full Text] [Related]
20. MIC of amoxicillin/clavulanate according to CLSI and EUCAST: discrepancies and clinical impact in patients with bloodstream infections due to Enterobacteriaceae.
Delgado-Valverde M; Valiente-Mendez A; Torres E; Almirante B; Gómez-Zorrilla S; Borrell N; Aller-García AI; Gurgui M; Almela M; Sanz M; Bou G; Martínez-Martínez L; Cantón R; Antonio Lepe J; Causse M; Gutiérrez-Gutiérrez B; Pascual Á; Rodríguez-Baño J;
J Antimicrob Chemother; 2017 May; 72(5):1478-1487. PubMed ID: 28093484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
